Onchilles Pharma

Today we announced the presentation of new preclinical data at at the 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗳𝗼𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿 𝟮𝟬𝟮𝟰 for the NEU-002 program, leveraging the ELANE pathway, a novel innate immune MOA for potent and selective cancer killing with the potential to treat a wide range of cancers. 📊 Title: NEU-002 leverages a cancer-specific innate immune pathway to induce immunogenic cell death and stimulate anti-tumor immunity #️⃣ Abstract #: 1297 📅 Date: Friday, November 8, 2024, 9:00 a.m. to 7:00 p.m. CST 📍 Location: George R. Brown Convention Center in Houston Read the release for more details:  https://lnkd.in/gW_NbBnT #SITC24 #SITC2024 #Immunotherapy #CancerResearch #Immunotherapies #cancer #tumor #oncology #novelMOA #anticancer #adaptiveimmunity #ELANEpathway #ELANE

Our cofounder Lev Becker chatted with PharmaShots about the excitement around our #AACR24 data, the difference between N17350 and N17465, and details for our upcoming #clinicaltrial. Read the article here: https://lnkd.in/gwbWUTY4 #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

We presented today at the 20th BioPharma Drug Discovery Nexus Conference in #SanDiego. Ravindra Gujar, Senior Scientist at Onchilles, gave a talk titled, “N17350 - A Novel Therapeutic Modality That Selectively Kills Cancer Cells and Induces Potent Anti-Tumor Immunity to Eradicate Tumors” If you missed it, read our recent data release: https://lnkd.in/gDzd42Fk #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

Our cofounders chatted with San Diego Business Journal about our recent #AACR24 data showing our lead drug candidate works across many cancer types to kill tumor cells but leave healthy cells alone – as well as how our upcoming clinical trial could quickly yield proof-of-concept data. Read the article here (subscription may be required): https://lnkd.in/gR-rCQzE #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

We presented at #AACR24 new preclinical data for tumor-directed N17350 and systemically delivered N17465 demonstrating the potential for potent and tumor-selective treatment for a wide range of cancers. Key points: ➡️ Tumor-directed N17350 and systemically delivered N17465 are based on the breakthrough discovery of a novel innate immune mechanism of action, which activates cell death pathways specific to cancer cells ➡️ New preclinical data demonstrate direct and tumor-selective efficacy of N17350 in both chemotherapy-naïve and -experienced ovarian cancer patient cells and cell-derived xenograft (CDX) models  ➡️ First data from the N17465 program demonstrate that the advanced drug lead can be delivered intravenously (IV) to induce potent single agent efficacy resulting from direct cancer cell killing and induction of anti-tumor immunity across a range of solid tumor models ➡️ Onchilles is on-track to initiate first-in-human clinical trials this year to evaluate N17350 in skin cancers, head and neck cancer, and triple-negative breast cancer Read the release here: https://lnkd.in/gDzd42Fk #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

We're unveiling at #AACR24 preclinical data on systemically delivered N17465 in an oral presentation and new preclinical data for tumor-directed N17350. Both leverage a novel innate immune mechanism of action and have the potential to treat a wide range of cancers. Read the release for more details: https://lnkd.in/geQZ53fK  #cancer #tumor #oncology #neutrophil #novelMOA #anticancer #adaptiveimmunity 

In this Q&A with Drug Target Review, our cofounder Dr. Lev Becker shares more about how our lead drug candidate, N17350, selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms. Read the interview here:  https://lnkd.in/gBEvg6VT 

While our poster presentation at #SITC23 is tomorrow, see the press release and poster on our website today. The data continue to support the unique profile of N17350 that combines potent and selective #cancer killing activity to eradicate #tumors independent of genetics and anatomical origin. We look forward to initiating our first-in-human clinical trials next year to evaluate N17350 in #skincancer, #headandneckcancer, and triple-negative #breastcancer.  https://lnkd.in/dPAj_2T2 #cancers #tumor #oncology #neutrophil #novelMOA #anticancer #adaptiveimmunity